Estados Unidos · Bolsa y Finanzas · Yahoo Finance

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Publicado por Yahoo Finance · Estados Unidos hace 10 h

BEIJING, Oct. 11, 2026 (GLOBE NEWSWIRE) -- (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced…

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

También te puede interesar

XRP Ledger defends emergency patch for unlimited XRP bug

Trump's Russia-Ukraine Energy Ceasefire May Only Cover Oil Refineries

Amazon in talks to acquire AI startup Decart for $7B: WSJ

The movie about a Facebook whistleblower who leaked incriminating details disappoints, and ‘The Social Reckoning’ will likely lag ‘The Social Network’

'SNL' takes aim at Kevin O’Leary and his Utah data center: 'I'm going to make the future go away’

Everyone wants SCOTUS to take up prediction markets: State of Crypto

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Compartir

También te puede interesar

XRP Ledger defends emergency patch for unlimited XRP bug

Trump's Russia-Ukraine Energy Ceasefire May Only Cover Oil Refineries

Amazon in talks to acquire AI startup Decart for $7B: WSJ

The movie about a Facebook whistleblower who leaked incriminating details disappoints, and ‘The Social Reckoning’ will likely lag ‘The Social Network’

'SNL' takes aim at Kevin O’Leary and his Utah data center: 'I'm going to make the future go away’

Everyone wants SCOTUS to take up prediction markets: State of Crypto